Figure 6.

Multivalent nanobodies demonstrate drug‐like biophysical properties. A) Apparent midpoint temperatures of the first unfolding transition (T _m ^*) of nanobody‐Fc fusion proteins. B) % monomer of nanobody‐Fc fusion proteins evaluated using size‐exclusion chromatography. C) Non‐specific binding of nanobody‐Fc fusion proteins. The nanobody‐Fc fusion proteins were immobilized on Protein A‐coated magnetic beads, incubated with biotinylated soluble membrane proteins, and non‐specific interactions were evaluated using flow cytometry. Control mAbs with high (emibetuzumab) and low (elotuzumab) levels of non‐specific interactions were also analyzed for reference. The data are averages of four (A), three (B), and two (C) independent repeats, and the error bars are standard deviations.